CytomX Therapeutics Inc (CTMX)
NASDAQ:CTMX
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.12Last Year’s EPS
0.27Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Positive — The call presented robust and clinically meaningful efficacy signals (ORR up to 32%, median PFS 6.8–7.1 months), compelling target validation, and clear reductions in the main severe toxicity (grade 3 diarrhea) through a combined strategy of AIBW dosing and dual prophylaxis. Remaining risks are primarily the need for larger/mature data (optimization cohorts, OS), ongoing management of diarrhea/electrolyte events, and confirmation of these early safety gains in bigger populations and combinations. Overall, the highlights materially outweigh the lowlights and support an optimistic near-term development trajectory.Company Guidance
Confirmed Objective Response Rates (ORR)
Strong antitumor activity with confirmed ORR of 32% at 10 mg/kg and 20% at 8.6 mg/kg in late-line metastatic CRC expansion cohorts.
Improved Progression-Free Survival (PFS)
Preliminary median PFS improved from 5.8 months (May 2025) to a range of 6.8–7.1 months (6.8 months at 8.6 mg/kg and 7.1 months at 10 mg/kg), representing ~17%–22% increase versus prior estimate.
Enrollment Growth and Trial Momentum
Total Phase I enrollment increased from 73 to 93 patients (an increase of 20 patients, ~27% growth) to support dose optimization and registrational planning.
Target Validation — High EpCAM Expression
EpCAM IHC consistently high across evaluable tumors (all H-scores >200, majority ≥250), supporting target selection and broad applicability in CRC.
Safety: Absence of Historical EpCAM and TOPOI ADC Toxicities
No evidence observed of prior EpCAM-associated severe toxicities (pancreatitis, severe liver toxicity) or interstitial lung disease seen with some TOP1 ADCs; no dose-limiting toxicities (DLTs) reported.
Meaningful Reduction in Severe Diarrhea with Dose Optimization
Implementation of adjusted ideal body-weight (AIBW) dosing plus mandatory dual prophylaxis (loperamide + budesonide) reduced grade 3 diarrhea from 29% (escalation/expansion) to 10% in early dose-optimization cohorts — a 19 percentage-point absolute reduction (~65% relative decrease versus 29%).
Durable Disease Control and Ongoing Treatment Duration
Durable responses observed with median follow-up >8 months; 16 patients remained on therapy at data cut with several on treatment >11 months.
Favorable PK Characteristics and Low Free Payload Exposure
Varseta-M PK is dose-proportional with mean half-life ~6–8 days; Varseta circulates primarily masked and unconjugated CAMP59 is low (~1%–3% of total), supporting therapeutic window and masked-PROBODY approach.
Clear Development Path and Near-Term Milestones
Company plans rapid advancement toward registrational studies (target start H1 2027), additional dose-optimization data and pivotal design details planned in H2 2026, and combination/expansion studies (bevacizumab combos, other tumor types) underway.
CTMX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CTMX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 16, 2026 | $4.68 | $6.75 | +44.23% |
Nov 06, 2025 | $4.19 | $3.62 | -13.60% |
Aug 07, 2025 | $2.10 | $2.35 | +11.90% |
May 12, 2025 | $0.93 | $2.13 | +129.53% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does CytomX Therapeutics Inc (CTMX) report earnings?
CytomX Therapeutics Inc (CTMX) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is CytomX Therapeutics Inc (CTMX) earnings time?
CytomX Therapeutics Inc (CTMX) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CTMX EPS forecast?
CTMX EPS forecast for the fiscal quarter 2026 (Q1) is -0.12.